Optimal treatment of the diabetic patient with multivessel disease.
Diabetes is emerging as a major source of cardiovascular morbidity and mortality. The atherosclerosis associated with diabetes has a complex etiology with even more complicated manifestations, such as multivessel and diffuse coronary disease. The optimal management of the diabetic patient with multivessel disease poses a special challenge in terms of the selection of the revascularization strategy and medical therapies. In this article, we assess the evidence accumulated to date and discuss ongoing studies that will help better inform this intricate decision-making process.
Bansilal
Sameer
S
Zena and Michael A. Wiener Cardiovascular Institute, Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine, New York, NY 10029, USA.
Farkouh
Michael E
ME
Fuster
Valentin
V
D015906:Angioplasty, Balloon, Coronary; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D003324:Coronary Artery Disease / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D048909:Diabetes Complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D006973:Hypertension / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
D000924:Anticholesteremic Agents; D001786:Blood Glucose; D010975:Platelet Aggregation Inhibitors